Procaspase-3 Activation as an Anti-Cancer Strategy: Structure-Activity Relationship of Procaspase-Activating Compound 1 (PAC-1) and its Cellular Co-Localization with Caspase-3

Por Peterson, Quinn P., Hsu, Danny C., Goode, David R., Novotny, Chris J., Totten, Ryan K., Hergenrother, Paul J.
Publicado em 2009

Parallel Synthesis and Biological Evaluation of 837 Analogues of Procaspase-Activating Compound 1 (PAC-1)

Por Hsu, Danny C., Roth, Howard S., West, Diana C., Botham, Rachel C., Novotny, Chris J., Schmid, Steven C., Hergenrother, Paul J.
Publicado em 2011

Discovery and Canine Preclinical Assessment of a Non-Toxic Procaspase-3-Activating Compound

Por Peterson, Quinn P., Hsu, Danny C., Novotny, Chris J., West, Diana C., Kim, Dewey, Schmit, Joanna M., Dirikolu, Levent, Hergenrother, Paul J., Fan, Timothy M.
Publicado em 2010

Pharmacokinetics and derivation of an anticancer dosing regimen for PAC-1 in healthy dogs

Por Lucas, Pamela W., Schmit, Joanna M., Peterson, Quinn P., West, Diana C., Hsu, Danny C., Novotny, Chris J., Dirikolu, Levent, Deorge, Daniel R., Garrett, Laura D., Hergenrother, Paul J., Fan, Timothy M.
Publicado em 2010